Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;57(4):1625-31.
doi: 10.1128/AAC.01573-12. Epub 2013 Jan 14.

Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum

Affiliations

Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum

Antigoni Elefanti et al. Antimicrob Agents Chemother. 2013 Apr.

Abstract

Given the high protein binding rates of antifungal drugs and the effect of serum proteins on Aspergillus growth, we investigated the in vitro pharmacodynamics of amphotericin B, voriconazole, and three echinocandins in the presence of human serum, assessing both inhibitory and fungicidal effects. In vitro inhibitory (IC) and fungicidal (FC) concentrations against 5 isolates of Aspergillus fumigatus, Aspergillus flavus, and Aspergillus terreus were determined with a CLSI M38-A2-based microdilution method using the XTT methodology after 48 h of incubation at 35 °C with a medium supplemented with 50% human serum. In the presence of serum, the IC and FC of amphotericin B and the IC of echinocandins were increased (1.21- to 13.44-fold), whereas voriconazole IC and FC were decreased (0.22- to 0.90-fold). The amphotericin B and voriconazole FC/IC ratios did not change significantly (0.59- to 2.33-fold) in the presence of serum, indicating that the FC increase was due to the IC increase. At echinocandin concentrations above the minimum effective concentration (MEC), fungal growth was reduced by 10 to 50% in the presence of human serum, resulting in complete inhibition of growth for some isolates. Thus, the in vitro activities of amphotericin B and echinocandins were reduced, whereas that of voriconazole was enhanced, in the presence of serum. These changes could not be predicted by the percentage of protein binding, indicating that other factors and/or secondary mechanisms may account for the observed in vitro activities of antifungal drugs against Aspergillus species in the presence of serum.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Concentration-effect curves of amphotericin B (A), voriconazole (B), and anidulafungin (C) with (open symbols and dashed regression lines) and without (closed symbols and solid regression lines) 50% serum based on inhibitory (circles and black lines) and fungicidal (squares and gray lines) activities against an Aspergillus flavus isolate. Error bars represent standard errors of the means, and lines are the regression lines of the Emax model. No fungicidal activity was found for anidulafungin. Horizontal dotted lines represent the level of 10% growth. Horizontal black and gray arrows represent the shift of inhibitory and fungicidal concentration-effect curves, respectively, whereas the vertical dotted arrow in panel C represents the reduction of the minimal growth Emin at supra-MEC concentrations.

Similar articles

Cited by

References

    1. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR. 2000. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79:250–260 - PubMed
    1. Groll AH, Walsh TJ. 2002. Antifungal chemotherapy: advances and perspectives. Swiss Med. Wkly. 132:303–311 - PubMed
    1. Johnson EM, Oakley KL, Radford SA, Moore CB, Warn P, Warnock DW, Denning DW. 2000. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J. Antimicrob. Chemother. 45:85–93 - PubMed
    1. Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW. 2001. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob. Agents Chemother. 45:1456–1462 - PMC - PubMed
    1. Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, Sein T, Schaufele R, Peter J, Bacher J, Casler H, Armstrong D, Espinel-Ingroff A, Rinaldi MG, Lyman CA. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188:305–319 - PubMed

LinkOut - more resources